Organic Active Ingredients TRIZ Cases

Oral TUDCA offers a well-tolerated way to slow ALS progression, delay functional decline, and improve quality of life alongside standard care.

Using R-152a propellant with low water and oxygen content stabilizes formoterol-budesonide MDI formulations at ambient temperature.

Distinct ALK inhibitor crystal forms use controlled crystallization and XRPD fingerprints to improve solubility, stability, and bioavailability.

A matrix patch uses lauryl lactate, long-chain fatty alcohols, and micronized risperidone to sustain 14-day delivery with less irritation.

By inhibiting Myosin II, pyridazinone compounds help limit muscle degeneration, inflammation, and fibrosis in DMD and BMD.

Flavagline derivatives target prohibitin to disrupt KRAS-CRAF binding, enabling selective KRAS4A/4B inhibition while sparing HRAS and NRAS.

Heating fatty acids with amino acids at 165°C or higher enables direct amidation with high conversion and lower product color, avoiding acid chlorides.

Amphiphilic self-assembled carriers protect peptide drugs from GI degradation while improving solubility and mucosal absorption.

Micronized actives in a water-soluble polymer film enable uniform dosing and precise dissolution profiles for consistent oral drug delivery.

Sequence-specific oligomeric agents lower PCDH19 RNA and protein to help reduce seizures and cognitive impairment in PCDH19-related disorders.

Quaternary ammonium linkers improve FAP inhibitor solubility, metabolic stability, and tissue penetration for better in vivo targeting.

WRG-28 and atovaquone are combined to inhibit CRAC and DDR2 activation, reducing fibrosis, cytokine storms, and metastasis.

Targeting PIP2 trafficking and GsdmD cleavage offers a way to reduce PFIC1 inflammation and hepatocyte damage linked to altered ATP8B1 function.

A preloaded balloon coating delivers therapeutic agents directly to non-vascular strictures, helping reduce recurrence and repeat procedures.

Defined aprocitentan sodium crystal forms improve stability, reduce hygroscopicity, and support reproducible pharmaceutical manufacturing.

Specific heterocyclic scaffolds block PD-L1 and PD-1 binding, expanding treatment options for cancer and other immune-related conditions.

Timed and enteric linkers plus polymer release coatings improve gastric residence control and reduce premature GI passage.

Targeting FOXM1 with a Ser25 mutant peptide or shRNA suppresses tumor growth, invasion, metastasis, and macrophage polarization.

Combining TTFields with IGF1R, JNK, RPS6, or ERK inhibitors helps overcome cancer cell resistance and increase apoptosis.

Combining ibudilast and bumetanide produces measurable EEG changes in ASD by reducing gamma waves and increasing alpha waves.

Modified nucleosides such as MOE improve antisense stability in plasma while strengthening TGF-β2 mRNA inhibition and cancer cell killing.

A quinazolinone BRAF inhibitor with brain penetration and pH-modified tablet delivery addresses efficacy and safety limits in melanoma brain metastases.

Non-coding RNA scaffolds package artificial microRNA hairpins into expression vectors, restoring microRNA function and regulating cancer pathways.

Chemically binding active agents to carbohydrates improves EV loading and intracellular delivery while avoiding membrane damage and aggregation.

Targeting OBSCN-AS1 with CRISPR activation restores OBSCN expression through chromatin remodeling to suppress breast cancer metastasis.

TLR7/TLR8 activation can worsen autoimmune disease, while Formula I compounds selectively inhibit these receptors to support treatment.

Controlled cleavage, cyclization, coupling, and purification raise omapatrilat yield while keeping optical purity high and impurities below 3%.

A Bf 844 compound approach broadens cancer treatment to BRCA-mutated and other hard-to-treat cancers while enhancing existing therapies.

Salt formation and controlled solid forms replace foam isolation and chromatography, cutting residual solvents while supporting stable BTK inhibitor scale-up.

Selective JAK1 inhibition targets IL-31-driven prurigo nodularis to reduce itch and nodules while avoiding broad immunosuppressant toxicity.

T790M EGFR mutations can resist existing therapies; combining plinabulin with osimertinib inhibits cancer growth and induces apoptosis.

Selective quinoline derivatives inhibit Factor XI activation to prevent thrombosis while improving potency and pharmacokinetic balance.

A phase-separated capsaicin emulsion raises drug loading and skin delivery while reducing burning sting pain and pretreatment needs.

A protein-coated grease core with a heat-cured colloid wall protects bioactive substances during sterilization, stirring, and acid exposure.

A CD33/CLL1 bispecific antibody linked to NK cells improves leukemia targeting and killing for relapsed or refractory AML.

Controlled enzymatic branching creates a high-molecular-weight glucan that digests slowly while retaining high digestibility.

A two-pot route combines key reaction and isolation steps to raise diazaspiro undecanone yield while avoiding hazardous reagents and cryogenic cooling.

Allosteric CRFR1 antagonists improve receptor selectivity and safety while reducing p-Tau levels and supporting cognition in AD models.

Separate tablet layers give metformin sustained release and enavogliflozin immediate release, improving uniformity and glucose control.

Oral apremilast dosage forms use controlled release and dose scheduling to support once-daily treatment with fewer gastrointestinal adverse effects.

Blocking nuclear export with inhibitors such as Selinexor helps oncolytic viruses replicate in nonpermissive tumor cells and kill cancer cells.

An antibody-drug conjugate targets BDCA2-positive cells with glucocorticoids, limiting non-targeted toxicity while suppressing inflammation.

Specific 3' hydrophobic substituents improve THRβ selectivity, boosting lipid metabolism while limiting THRα-linked side effects.

Hydroxypropyl cellulose keeps rotigotine dissolved in silicone adhesive, helping prevent crystals while supporting stable transdermal delivery.

Novel cilostazol-derived compounds cross the blood-brain barrier to curb glioblastoma proliferation and slow tumor growth.

An alginate oral film delivers sumatriptan non-invasively while achieving faster, more consistent plasma levels than tablets or nasal sprays.

Specific Formula (I) compounds selectively inhibit TIPARP while minimizing PARP1 and PARP2 inhibition to reduce cytokine-related side effects.

A hydrophilic polymer inner layer and amphiphilic lipid shell limit transit drug loss, prevent burst release, and improve bioavailability.

Dual JAK1/JAK2 and BET inhibition improves myeloproliferative neoplasm control by suppressing inflammatory signaling beyond single-agent therapy.

An isolated Torilidis Fructus compound reduces cancer-cell viability while minimally affecting normal cells across multiple cancer types.